SCHEMBL4882490

SCHEMBL4882490

Cc1ccc(-n2nc3c(c2N)CSC3)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.49
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
KDM4E B2RXH2 3/20 0.45
MAPT P10636 3/20 0.45
POLB P06746 2/20 0.45
HTT P42858 2/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4881920 0.84 TP53 (0.47) TSHRMEN1KMT2AMAPTLMNA
SCHEMBL4940565 0.84 MAPT (0.47) MEN1KMT2AMAPTPOLBLMNA
SCHEMBL3145312 0.84 MAPT (0.49) TSHRALDH1A1MEN1KMT2AMAPT
SCHEMBL12335137 0.67 ALDH1A1 (0.54) TSHRALDH1A1MEN1KMT2ACYP1A2
SCHEMBL16486063 0.67 ALDH1A1 (0.54) TSHRALDH1A1MEN1KMT2ACYP1A2
SCHEMBL16866554 0.67 MAPT (0.38) TSHRALDH1A1MEN1KMT2ACYP1A2
SCHEMBL16866552 0.66 MAPT (0.37) TSHRALDH1A1MEN1KMT2ACYP1A2
SCHEMBL19643165 0.65 ALDH1A1 (0.51) TSHRALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1074593 0.65 RAB9A (0.45) TSHRALDH1A1MEN1KMT2AHSD17B10
SCHEMBL12783194 0.64 MAPT (0.46) ALDH1A1MEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249154-A1 Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates ONO PHARMACEUTICAL CO., LTD. (JP) 2008-10-09 US disclosed
EP-1698335-A1 PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249154-A1 Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates MTNR1A, GSR, NLN TSHR 214/4885ALDH1A1 1371/4885MEN1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.